Associations between serum estradiol and IL-6/sIL-6R/sgp130 complex in female patients with major depressive disorder

BMC Psychiatry

Research

Qian Chen¹  Junchi Mei¹  Ting Sun¹  Yan Li¹ 

[1] Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Zhangzhidong Road, Wuchang District, 430060, Wuhan, Hubei, China;

关键词: Major depressive disorder;    Estradiol;    Soluble glycoprotein 130;    Soluble interleukin-6 receptor α;    Interleukin-6;   

DOI  :  10.1186/s12888-023-05248-z

 received in 2023-05-30, accepted in 2023-10-03,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundIt has been hypothesized that the IL-6/sIL-6R/sgp130 complex, an inflammatory complex, plays a critical role in the pathogenesis of major depressive disorder (MDD). Estradiol (E2) is a sex steroid hormone involved in emotional regulation and MDD. This study aimed to investigate the relationship between E2 and IL-6/sIL-6R/sgp130 complex in patients with MDD.MethodsUsing enzyme-linked immunosorbent assay, the levels of IL-6, sIL-6Rα, and sgp130 were compared between 117 female patients with MDD and 122 healthy controls.The serum concentrations of E2 and other biomarkers were also measured.Results(1) The serum levels of IL-6 and sIL-6Rα in patients with MDD were significantly higher than those in the control group, while the serum levels of sgp130 and E2 were significantly lower (all P < 0.05). (2) Low levels of E2 were associated with high levels of IL-6 and low levels of sgp130 (all P < 0.01). (3) HAMD-24 score was positively correlated with the serum level of IL-6, but negatively correlated with the serum levels of sgp130 and E2(all P < 0.05). (4) IL-6 and sgp130 had certain prognostic values in MDD, and the combination of various indicators showed a significantly superior prognostic value.ConclusionsThe IL6/sIL-6R/sgp130 complex in female patients with MDD was closely related to E2 level. In addition, IL-6 and sgp130 may be valuable serum biomarkers for the diagnosis and prognosis of MDD in women.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 3

Fig. 2

Fig. 1